PharmaCyte Biotech (PMCB) Change in Cash (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Change in Cash of -$1.6 million for Q2 2026, down 28.92% year-over-year from -$2.2 million in Q2 2025, and down 132.81% quarter-over-quarter from $4.8 million in Q1 2026.
PharmaCyte Biotech (PMCB) Change in Cash (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Change in Cash for 17 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Cash fell 28.92% year-over-year to -$1.6 million; the TTM figure through Apr 2026 stood at $3.4 million (up 109.8% YoY), while the FY2026 annual figure was $3.4 million, up 109.8% from the prior year.
- Change in Cash slipped to -$1.6 million in Q2 2026 per PMCB's latest filing, from $4.8 million in the prior quarter.
- Across five years, Change in Cash topped out at $6.6 million in Q3 2023 and bottomed at -$17.5 million in Q3 2024.
- Historically, Change in Cash has averaged -$3.8 million across 5 years, with a median of -$2.6 million in 2022.
- On a YoY basis, Change in Cash climbed as much as 308.71% in 2023 and fell as far as 1346.31% in 2023.
- PharmaCyte Biotech's Change in Cash stood at -$5.3 million in 2022, then jumped by 76.5% to -$1.2 million in 2023, then tumbled by 853.32% to -$11.8 million in 2024, then soared by 118.89% to $2.2 million in 2025, then slumped by 170.1% to -$1.6 million in 2026.
- Business Quant data shows PMCB's Change in Cash at -$1.6 million in Q2 2026, $4.8 million in Q1 2026, and $2.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | -1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -1.56 Mn |
| Jan 31, 2026 | 4.76 Mn |
| Oct 31, 2025 | 2.23 Mn |
| Jul 31, 2025 | -1.99 Mn |
| Apr 30, 2025 | -1.21 Mn |
| Jan 31, 2025 | -4.46 Mn |
| Oct 31, 2024 | -11.80 Mn |
| Jul 31, 2024 | -17.54 Mn |
| Apr 30, 2024 | -11.03 Mn |
| Jan 31, 2024 | -12.21 Mn |
| Oct 31, 2023 | -1.24 Mn |
| Jul 31, 2023 | 6.62 Mn |
| Apr 30, 2023 | -4.60 Mn |
| Jan 31, 2023 | -4.32 Mn |
| Oct 31, 2022 | -5.27 Mn |
| Jul 31, 2022 | -3.17 Mn |
| Apr 30, 2022 | -1.24 Mn |
| Jan 31, 2022 | -298,855.00 |
| Oct 31, 2021 | 85.98 Mn |
| Jul 31, 2021 | -1.24 Mn |